十四种新冠疫苗伤害补偿制度及索赔批准率的比较分析
本研究比较了14个无过错疫苗伤害补偿制度的结构与有效性,分析新冠疫苗伤害索赔的批准率。共纳入167,532份申请,已审核索赔中最高137,076份、批准最高38,658份。各辖区批准率差异大,日本最高(74.29%),美国(3%)和英国(2.64%)最低,14个辖区中位批准率为26.76%。
要点
- 14个辖区新冠疫苗伤害补偿索赔批准率差异大,日本74.29%最高,美国3%、英国2.64%最低。
- 14个辖区中位批准率为26.76%,介于韩国26.09%与法国27.42%之间。
- 资金来源与批准率无明确相关性,法国和日本政府资助制度批准率较高,美英类似模式批准率低。
核心结论
- 政府可参考国际实践和最新医学证据,采用更灵活的疫苗伤害补偿标准。
- 高批准率国家提供了包容性标准的见解,低批准率国家可能需要重新评估严格标准。
- 中间地带国家可纳入新的医学发现以完善标准,确保疫苗伤害受影响者获得公平结果。
研究设计与样本
- 本研究考察14个无过错疫苗伤害补偿制度的结构与有效性,分析新冠疫苗伤害索赔批准率数据。
- 数据来源包括政府报告和学术研究,用于比较不同运营模式和资金来源。
主要发现
- 本研究纳入167,532份新冠疫苗伤害补偿申请,已审核索赔最高137,076份,批准最高38,658份,含精确和近似官方数字。
- 已审核索赔的批准率在各辖区差异很大,日本最高(74.29%),美国(3%)和英国(2.64%)最低。
- 14个辖区中位批准率为26.76%,介于韩国26.09%与法国27.42%之间。
- 资金来源与批准率之间无明确相关性,例如法国和日本政府资助制度批准率较高,而美国和英国类似模式批准率低。
- 在新西兰及其他拥有更广泛医疗补偿制度的国家,批准率高于国际中位数。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: No-fault vaccine injury compensation schemes provide financial redress for adverse effects from vaccines without establishing fault. Due to the rapid vaccine development and distribution, these programs are crucial for vaccinees during the COVID-19 pandemic. Investigating the performance differences of these schemes worldwide and finding a more balanced approach is essential to responses to future pandemics. MATERIALS AND METHODS: This study examines the structure and effectiveness of 14 no-fault vaccine injury compensation schemes, analyzing data on approval rates for COVID-19 vaccine injury claims. Data sources include government reports and academic studies to compare diverse operational models and funding sources. RESULTS: This study included 167,532 COVID-19 vaccine injury compensation applications, with up to 137,076 claims reviewed and up to 38,658 approved, incorporating both exact and approximate official numbers. Approval rates for the reviewed claims vary widely across jurisdictions, with Japan (74.29 %) having the highest rates, and the United States (3 %) and the United Kingdom (2.64 %) the lowest. The median approval rate across all 14 jurisdictions is 26.76 %, between South Korea's 26.09 % and France's 27.42 %. These variations reflect diverse standards and policies. No clear correlation exists between funding sources and approval rates. For example, government-funded schemes in France and Japan show higher approval rates, while similar models in the United States and the United Kingdom have low rates. In New Zealand and other countries with broader medical compensation schemes, approval rates are higher than the international median. CONCLUSION: Governments may adopt more flexible standards to redress vaccine injuries by referring to international practices and the latest medical evidence. High-approval-rate countries offer insights into inclusive criteria, while low-approval-rate countries may need to reassess stringent criteria. Middle-ground countries could incorporate new medical findings to refine standards, ensuring equitable outcomes for those affected by vaccine injuries.
引用
- Chu CF, Chang TH, Ho JJ, et al. Comparative analysis of fourteen COVID-19 vaccine injury compensation systems and claim approval rates. Vaccine. 2025. PMID: 40037238. doi:10.1016/j.vaccine.2025.126830
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。